A once-daily maintenance dose of vonoprazan 10 mg or 20 mg may be a suitable substitute to lansoprazole in reducing the risk of erosive oesophagitis (EE) recurrence, according to a phase III noninferiority study presented at DDW 2020.
The guanylate cyclase-C receptor agonist plecanatide is effective and well-tolerated by older individuals (≥65 years) with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), results of a post hoc analysis presented at DDW 2020 has shown.
Maintenance therapy with a new subcutaneous (SC) formulation of the monoclonal antibody vedolizumab led to improvements in patient-reported outcomes (PROs) in patients with moderate-to-severe active Crohn’s disease (CD) compared with placebo, interim results of the phase III VISIBLE 2 study has shown.
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.